Pancreatic Cancer Treatment Market – By Cancer Type (Exocrine, Endocrine), Treatment Type (Chemotherapy, Immunotherapy, Hormone & Targeted Therapy), Route of Administration (Oral, Parenteral), Gender (Male, Female), End-use & Forecast (2024 – 2032)

Pancreatic Cancer Treatment Market Size

Pancreatic Cancer Treatment Market was valued at USD 3 billion in 2023 and is anticipated to witness growth at a CAGR of 13.2% over the analysis period. Increasing prevalence of pancreatic cancer globally has created a pressing demand for effective treatment options.
 

For instance, as per the World Cancer Research Fund International, pancreatic cancer is the 12th most common cancer worldwide and there were more than 495,000 new cases of pancreatic cancer in 2020. Such high number of pancreatic cancer cases increases the demand for effective treatments, thereby propelling the market growth. Additionally, the expanding geriatric population, which is more susceptible to pancreatic cancer, also contributes to market growth. Moreover, significant investments in research and development by pharmaceutical companies have resulted in innovative treatments, including targeted therapy and cancer immunotherapy, further fostering a favorable environment for market expansion.
 

Pancreatic cancer treatment involves various approaches aimed at eradicating or controlling the growth of cancer cells in the pancreas. The treatment involves a multidisciplinary approach that includes chemotherapy, targeted therapy, radiotherapy, surgery, and supportive care. The specific treatment options depend on the stage of the cancer at diagnosis.
 

Pancreatic Cancer Treatment Market Trends

• The escalating incidence and prevalence of pancreatic cancer stands as a pivotal catalyst propelling the growth of the market.
   
• Pancreatic cancer, characterized by its aggressive nature and often late-stage diagnosis, has witnessed a surge in cases globally.
   
• For instance, globally, 458,918 new cases of pancreatic cancer have been reported in 2018, and 355,317 new cases are estimated to occur until 2040. The largest increase is expected in Asia, with a projected 88.8% rise in new cases from 2018 to 2040. Such high prevalence of pancreatic cancer cases will spur the demand for effective therapies, thus fostering the market growth.
   
• Factors such as aging populations, lifestyle changes, and environmental factors contribute significantly to this rise. As the burden of pancreatic cancer continues to increase, the market for pancreatic cancer treatments is poised for substantial expansion in the coming years.
   

Pancreatic Cancer Treatment Market Analysis

Based on cancer type, the market is segmented into exocrine pancreatic cancer and endocrine pancreatic cancer. The exocrine pancreatic cancer segment dominated the market in 2023 and accounted for USD 2.6 billion.
 

• Exocrine pancreatic cancer, which includes adenocarcinoma, is the most common type of pancreatic cancer, accounting for nearly 85% of cases. This high prevalence contributes significantly to the segment's market share.
   
• Additionally, advancements in treatment options, such as surgery, chemotherapy, and targeted therapy, have improved outcomes for patients with exocrine pancreatic cancer, thereby boosting the segment's market share.
   
• Moreover, the segment benefits from extensive research and development efforts focused on understanding the molecular mechanisms and genetic mutations associated with exocrine pancreatic cancer, thus further driving segmental growth.

Based on treatment type, the pancreatic cancer treatment market is segmented into chemotherapy, targeted therapy, immunotherapy, hormone therapy, and other treatment types. The targeted therapy segment dominated the market with 38.2% of market share in 2023.
 

• The targeted therapy segment holds a high market share in the pancreatic cancer treatment industry due to its precision and effectiveness in combating this challenging disease.
   
• Unlike traditional chemotherapy, targeted therapies are designed to specifically target cancer cells while minimizing damage to healthy cells, thereby reducing side effects. These therapies often work by targeting specific molecules or pathways involved in the growth and survival of cancer cells.
   
• With advancements in understanding pancreatic cancer biology, targeted therapies have emerged as a promising approach, thereby driving its adoption in the overall treatment landscape.
   

Based on route of administration, the market is segmented into oral and parenteral. The parenteral segment held highest market share in 2023 and is anticipated to grow at a CAGR of 13% over the forecast years.
 

• Parenteral administration offers a direct and efficient delivery method for chemotherapy drugs and other therapies used in pancreatic cancer treatment. This route bypasses the digestive system, ensuring a higher concentration of the drug reaches the target site.
   
• The parenteral route also allows for more precise dosing and the ability to administer multiple drugs simultaneously, which is often necessary in the complex treatment regimens for pancreatic cancer.
   
• Overall, the convenience, effectiveness, and necessity of parenteral administration contribute to its high market share in the pancreatic cancer treatment landscape.
   

Based on gender, the pancreatic cancer treatment market is segmented into male and female. The male segment dominated the market in 2023 with 57.4% market share.
 

• Pancreatic cancer is more common in men than in women leading to a larger patient population among males.
   
• For instance, globally, the incidence of pancreatic cancer is 5.5 per 100,000 for men and 4.0 per 100,000 for women.
   
• This can be attributed to higher incidence of risk factors among men, such as environmental or occupational risk factors, heavy smoking habits, and high alcohol intake.
   
• All these factors together contribute to high market share of male segment in the pancreatic treatment market.
   

Based on end-use, the pancreatic cancer treatment industry is segmented into hospitals, oncology centers, and other end-users. The hospitals segment dominated the market in 2023 and is anticipated to reach USD 4.8 billion by 2032.
 

• Hospitals are often the primary healthcare providers for cancer patients, offering a range of treatment options such as surgery, c  hemotherapy, radiation therapy, and targeted therapy. They also provide comprehensive care facilities, including specialized oncology departments and access to clinical trials.
   
• Additionally, hospitals have the necessary infrastructure and expertise to handle complex cases, including advanced stage pancreatic cancer, which often requires multidisciplinary approaches.
   
• As a result, patients prefer hospitals for their cancer treatment, contributing to the high market share of this segment in the market.

North America market was valued at USD 1.2 billion in 2023 and is anticipated to reach USD 3.5 billion by 2032.
 

• North America holds a significant share in the pancreatic cancer treatment industry, primarily due to advanced healthcare infrastructure, high adoption of novel therapeutics, and a strong focus on research and development.
   
• The region is home to several key pharmaceutical and biotechnology companies engaged in developing innovative treatments for pancreatic cancer.
   
• Additionally, the presence of leading healthcare facilities and a high prevalence of pancreatic cancer cases contribute to the region's dominance in the market.
   

The U.S. market is anticipated to grow at a CAGR of 12.7% between 2024 - 2032.
 

• The U.S. holds a significant share in the pancreatic cancer treatment market, primarily due to high incidence of pancreatic cancer cases in the country.
   
• For instance, as per the Hirshberg Foundation for Pancreatic Cancer Research, in 2024, an estimated 66,440 new cases of pancreatic cancer are projected in the U.S., with over 51,750 expected deaths from the disease.
   
• Additionally, advanced healthcare infrastructure in the country, robust research and development activities, and high adoption rate of novel therapies, further drives the market growth.
   
• Moreover, the U.S. has a well-established regulatory framework that facilitates the swift approval of new therapies, further bolstering its position in the market.
   

UK is anticipated to witness robust growth in the global market.
 

• The country boasts a robust healthcare infrastructure and a well-established research ecosystem, fostering innovation and the development of novel therapies.
   
• Additionally, with a growing aging population and an increasing awareness about pancreatic cancer, there's a rising demand for advanced treatment options.
   
• Moreover, collaborations between academia, industry, and healthcare providers further propel the market growth.
   

India pancreatic cancer treatment industry is anticipated to witness lucrative growth between 2024 – 2032.
 

• India has emerged as a promising market for pancreatic cancer treatment, showcasing significant growth potential. Several factors contribute to this trend, including the increasing incidence of pancreatic cancer in the country, driven by various lifestyle factors and aging population.
   
• Additionally, advancements in medical infrastructure, diagnostic capabilities, and access to novel treatment options, such as targeted therapies and immunotherapy, are further fueling the market growth.
   
• Moreover, the rising healthcare expenditure and government initiatives aimed at improving cancer care and awareness are creating a conducive environment for market expansion.
   

Pancreatic Cancer Treatment Market Share

The competitive landscape of the market is characterized by a mix of established pharmaceutical companies, biotechnology firms, and research institutions striving to develop effective therapies for this challenging disease. Key players such as Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, and Pfizer Inc. are actively engaged in the development of novel treatment options. These companies often collaborate with academic institutions and research organizations to advance their pipelines.
 

Pancreatic Cancer Treatment Market Companies

Prominent players operating in the Pancreatic Cancer Treatment industry include:

• AstraZeneca
• Bristol-Myers Squibb Company
• Celgene Corporation
• Eli Lilly and Company
• Genentech (F. Hoffmann-La Roche Ltd.)
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Mylan N.V.
• Novartis AG
• PharmaCyte Biotech, Inc.
• Pfizer, Inc.
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
   

Pancreatic Cancer Treatment Industry News:

• In December 2019, AstraZeneca and Merck received the U.S. Food and Drug Administration (FDA) approval for LYNPARZA for maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma. This helped the company increase sales of its product.
   
• In May 2019, Mylan N.V. announced the U.S. launch of Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg, a generic version of Genentech's Tarceva. Mylan Pharmaceuticals received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. It is indicated as a first-line treatment for patients with locally advanced, unresectable, or metastatic pancreatic cancer, in combination with gemcitabine. This helped the company expand the applications of its product.
   

The pancreatic cancer treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Cancer Type

• Exocrine pancreatic cancer
• Endocrine pancreatic cancer

Market, By Treatment Type

• Chemotherapy
• Targeted therapy
• Immunotherapy
• Hormone therapy
• Other treatment types

Market, By Route of Administration

• Oral
• Parenteral

Market, By Gender

• Male
• Female

Market, By End-use

• Hospitals
• Oncology centers
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa